• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Logo
  • COVID-19 Resource Center
  • Categories
    • Feature
    • Cardiology trends
    • Cardiology research news
    • Conference coverage
    • Consensus reports & Position papers
    • Resources for Cardiology Professionals
    • COVID-19 Resource Center
  • Videos
  • Cardiology Best Practices

Cardiology Update

The latest trends and advancements made in cardiology research.

Albiglutide to lower risk of cardiovascular events

January 30, 2019

Reading Time: 2 minutes

Patients with type 2 diabetes have an elevated risk of cardiovascular events; Hernandez et al. wondered if a once-weekly injection of albiglutide might mitigate this risk.  The Harmony trial consisted of a double-blind, randomized, placebo-controlled trial at 610 sites throughout 28 countries.  The trial assigned, in a 1:1 ratio, 9463 patients consisting of men and women aged 40 years or older with a diagnosis of type 2 diabetes and pre-existing cardiovascular disease to receive either a once weekly injection of albiglutide (30-50mg) or a placebo injection, in addition to usual care. 

After a median duration of 1.6 years, first occurrence of cardiovascular death, myocardial infarction or stroke (the primary outcome) was lower in the albiglutide group than in the placebo group (7% vs. 9%; hazard ratio 0.78; p < 0.0001 for non-inferiority; p = 0.0006 for superiority.)

These results translate to a 22% reduction of risk of the primary outcome.  Therefore, the researchers conclude that the addition of once-weekly injections of albiglutide to current standard care protocol would result in better cardiovascular outcomes in patients with type 2 diabetes.

Albiglutide
(Tanzeum®, Eperzan®)

Albiglutide is indicated to improve glycaemic control in patients with type 2 diabetes mellitus.
Administered once weekly by subcutaneous injection.
As a glucagon-like peptide-1 (GLP-1) receptor agonist, albiglutide functions to elevate intracellular cyclic AMP in pancreatic beta cells. This in turn leads to glucose-dependent insulin release, reduces glucagon secretion. It also delays gastric emptying and reduces food intake.
Numerous studies have shown benefits of using albiglutide as monotherapy or as an adjunct to other antidiabetic agents for improving glycaemic control in patients with type 2 diabetes.

Original article: Drugs. 2015 Apr;75(6):651-63.
Author: Nazanin Hakimzadeh

Original article: Lancet. 2018 Oct; 392:1519-29.

Author: Kelly Schoonderwoerd


Check Out Related Articles

  • Coronary CTA: are there therapeutic benefits at five years?Coronary CTA: are there therapeutic benefits at five years?
  • EXCEL trial: Repeat revascularization after CABG and PCI for left main diseaseEXCEL trial: Repeat revascularization after CABG and PCI for left main disease
  • Top 10 Highlights of AHA 2020 CongressTop 10 Highlights of AHA 2020 Congress

Primary Sidebar

Cardiology News Highlights

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Most featured

Statin therapy: clinical benefits and potential risks

Statin therapies prevent both primary and secondary cardiovascular disease.However, long term safety … Continue Reading about Statin therapy: clinical benefits and potential risks

Cardiology Conferences 2021

Top Cardiology Conferences 2021

With the COVID-19 worldwide pandemic, conferences and congresses planned for 2020 converted to … Continue Reading about Top Cardiology Conferences 2021

N of 1 Trial - Statin side effects

SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

The phenomenon of non-adherence to statin therapy is well known. Reasons for discontinuation include … Continue Reading about SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Footer

Cardiology Update

Providing up-to-date developments in the field of cardiology in a clear and concise manner. All articles are written by professional medical journalists and subsequently reviewed by our editorial board. Cardiology Update provides breaking news, that matter to healthcare professionals in the field of cardiology. Subscribe for free to keep up with cardiology news updated regularly.

Learn More About Us

Contact Us

Recent

  • Top Cardiology Conferences 2021
  • SAMSON Trial: Role of nocebo effect in statin-associated muscle symptoms
  • Top 10 Highlights of AHA 2020 Congress
  • Thromboembolism in COVID-19 patients despite thromboprophylaxis
  • Top 10 highlights of TCT 2020 Congress

Search

Browse by topic

Cardiac surgery Electrophysiology General cardiology Heart failure Imaging Interventional cardiology

Terms & Conditions | Privacy | Disclaimer
© Clinicalinx B.V. All rights reserved. Postbus 2278, 1000 CG Amsterdam

We use cookies to provide the services and features offered on our website, and to improve our user experience. Learn more Ok
Privacy & Cookies Policy
Necessary Always Enabled